

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Adamou et al.

Application Serial No.: To Be Assigned

Art Unit: To Be Assigned

Filed: Concurrently Herewith

Examiner: To Be Assigned

For: Calcitonin Gene Related Peptide Receptor

Atty. Docket: PF129C2

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
Washington, D.C. 20231

S I R:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-BB listed on the attached form PTO/SB/08.

Copies of references AA-BB were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 09/455,442, filed December 6, 1999, and related U. S. Patent Application Serial No. 08/461,250, filed June 5, 1995, to which applications the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the files of U. S. Patent Application Serial Nos. 09/455,442 and 08/461,250 for copies of references AA-BB.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Dated: 1/22/02


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 251-6015

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	Adamou, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	3	Attorney Docket Number	PF129C2

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	5,334,521		Ishikawa et al.	08/1994	
	AB	5,508,164		Kausch et al.	04/1996	
	AC	5,516,651		Goldring et al.	05/1996	
	AD	5,622,839		Moore et al.	04/1997	
	AE	6,074,845		Aiyar et al.	06-13-2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AF		WO 94/08006		Zymogenetics, Inc.	04-14-1994		
	AG		WO 92/01810		Lerner et al.	02-06-1992		
	AH		WO 96/04928		Human Genome Sciences, Inc.	02-22-1996		
	AI		WO 96/05221		Human Genome Sciences, Inc.	02-22-1996		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	AJ	AIYAR et al., "A cDNA Encoding the Calcitonin Gene-related Peptide...", <i>J. of Biol. Chem.</i> , 271(19):11325-11329 (02-20-1996)			
	AK	BOWIE et al., Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", <i>Science</i> 247:1307-1310 (1990)			
	AL	FLUHMANN et al. "A Human Orphan Calcitonin Receptor-Like Structure" <i>Biochem. & Biophys. Res. Comms.</i> Vol 206(1):341-347 (1995)			
	AM	GEORGE et al., "Current Methods in Sequence Comparison and Analysis", Macromolecular Sequencing and Synthesis (ed. by D.H. Schlesinger) Alan R. Liss Inc., New York, pp. 127-149 (1988)			
	AN	HODGSON, "Receptor Screening and the Search for New Pharmaceuticals", <i>Bio Technology</i> 10:973-975 (1992)			
	AO	ISHIHARA et al., Molecular Cloning and Expression of a cDNA Encoding the Secretin Receptor", <i>The EMBO J.</i> 10(7):1635-1641 (1991)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

jc872 U.S. PTO
10/051186
01/22/02

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	Adamou, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	PF129C2

U.S. PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	AP	MUFF et al., "Comparison of a Calcitonin Gene-Related Peptide Receptor in a Human...", <i>Annals of the New York Academy of Sciences</i> , Vol. 657, pgs. 106-116 (1992).		
	AQ	NJUKI et al., "A New Calcitonin-receptor-like Sequence in Rat Pulmonary Blood Vessels", <i>Clinical Science</i> , Vol 85:385-388 (1993)		
	AR	WALLACE et al., "Methods in Enzymology" 152:432-442 (1987)		
	AS	WATSON et al. The G-Protein Linked Receptor Factsbook; Academic Press Limited, San Diego, FCA; pp. 2-6 (1994)		
	AT	FOORD, et al., "Isolation and Characterisation of a Human Calcitonin-Gene-Related-Peptide Receptor", <i>Eur. J. Biochem.</i> Vol. 170:373-379 (1987)		
	AU	Biochemistry, Vol 30:(12)2993-2999 (1991)		
	AV	LIN et al., "Expression Cloning of an Adenylate-Cyclase-Coupled Calcitonin Receptor", <i>Science</i> 254:1022-1024 (1991)		
	AW	CHABRE et al., "A Recombinant Calcitonin Receptor Independently Stimulates 3,5-Cyclic Adenosine Monophosphate and Ca ²⁺ /Inositol Phosphate Signaling Pathways," <i>Molec. Endocrin.</i> , Vol 6(4):551-556 (1992)		
	AX	WATSON, S.P. (ed.) "Calcitonin Gene-Related Peptide: Multiple Actions, Multiple Receptors," <i>Pharmac. Ther.</i> 56:23-51 (1992)		
	AY	GOLDRING et al., "Characterization of the Structural and Functional Properties of Cloned Calcitonin Receptor cDNAs," <i>Horm. Metab. Res.</i> Vol 25:477-480 (1993).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	Adamou, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	PF129C2

U.S. PATENT DOCUMENTS						
Examiner Initials ⁶	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ⁶	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ⁶	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	AZ	CHANG, et al. "Identification of a Seven Transmembrane Helix Receptor for Corticotropin-Releasing...", <i>Neuron</i> , Vol 11:1187-1195 (1993)		
	BA	WIMALAWANSA et al., "Isolation Purification, and Characterization of Calcitonin Gene-Related Peptide Receptor", <i>Peptides</i> , Vol. 14:691-699 (1993)		
	BB	COOPER, G.J.S., "Amylin Compared with Calcitonin Gene-Related Peptide: Structure, Biology, and Relevant to Metabolic Disease," <i>Endocrine Review</i> 15(2):163-201 (1994)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231